Laserterapia He-Ne en la regeneración hística de las quemaduras

Presentamos un estudio experimental de las posibilidades de utilización del láser He-Ne sobre la aceleración de la regeneración tisular en quemaduras producidas por ácido.We present an experimental study of the possibilities of using the He-Ne laser on the acceleration of tissue regeneration in burns caused by acid.peerReviewe

La radiación láser en la cicatrización de lesiones superficiales en la mucosa del caballo

Se presenta un estudio experimental de las posibilidades de utilización de la terapia láser, en la regeneración tisular de las lesiones superficiales de la mucosa oral de los équidos. Se realizan un total de 42 infiltraciones de O,1 ml de una solución de ácido sulfúrico al 9,8 % en la mucosa del labio mandibular, que posteriormente son tratadas con dos equipos de láser, helio-neón e infrarrojos. Los resultados macroscópicos y microscópicos permiten afirmar que la radiación láser He-Ne favorece una más rápida, enérgica y perfecta cicatrización de las lesiones irradiadas.An experimental study was made about the use of lasertherapy in the promotion of tissue regeneration in superficial lesions of the equine mucosa. 42 infiltrations were made, each of O,1 ml of 9,8% sulphuric acid solution, into mucosa of the lip. Theses infiltrations were treated with two lasers equipment, Helium-Neon and lnfrared. Macroscopic and microscopic results showed that Helium-Neon laser irradiation improved speed, vigour and quality of cicatrization.peerReviewe

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols